- NewsCategory：
- All Company news Industry news
common83One result
-
1017
WindMIL Therapeutics and Un÷↑≤iversity of California, Irvine A™ nnounce Collaboration to★£♦₩ Collect Bone Marrow >β↓from Patients with Gliomas
WindMIL Therapeutics and ♣÷πUniversity of Califo≤&Ωrnia, Irvine Announce Collaboration to •☆Collect Bone Marrow from Patients with GliomasWE₩•<DNESDAY, OCTOBER 16, 2019WindMIL Th↑∏erapeutics and the Univers πity of California, Irvδ≠✔→ine (UCI) today announced that the first pati✘≈ents have been identifie₹≤→ d in an investigator-sponsorγ•ed study for the coll₽™Ωection of bone marrow from patients with ↓≥gliomas. The study will evaluate generating ma€← ≈rrow infiltrating lymphocytes (MILs™) ₹δfor these patients through WindMIL’sΩ' proprietary cellular a÷↑ctivation and expansion process. The study is bei₽★ng conducted at UCI.“Patients sδ→uffering with glioblastoma are in →•≠great need of new, promis&εφing treatments that mig&&ht advance the current standard of care,” said D∞ Ω aniela A. Bota, MD, PhD, direct✘₩or of the UCI Health C ™omprehensive Brain Tumor Program, sen☆←×✔ior associate dean for δ∏"clinical research, UCI S"¥chool of Medicine and clinical ×♥₽director, UCI Sue & Bill Gross£ ¶ Stem Cell Research Center. “The Uni γversity of California, Irv€♠ine is excited to play a key rol♣★≤e in research that may lead to a clinical★$ trial that enlists the ™α✘$immune system in novel ways to fight this terrib>↑•le disease.”Gliomas are the most common of t•×γhe malignant brain tumors. Gliobl→★✘≥astoma, the most common glioma, ha ★→₩s a five-year survival of less thaβφ≈§n 5 percent. Additional tre"×↓atment options are urgently needed for these pat •ients. Adoptive immunotherapy is a®δ possible approach for glio¶'πmas and the use of MILs, a cell the±←rapy that is naturally tumor-speci≈♦↕fic, is one such treatment option.Th ★€$e bone marrow is a unique niche in "↔♦the immune system to which antigen-exper↑£&ienced memory T cells traffic and ar§£e then maintained. WindMIL has developed a propδ★rietary process to select, acβ↓★tivate and expand these memory T cells ↓αinto MILs. Because memory T cells in bone marrow φλoccur as a result of the immu≈'∞ne system’s recognition of tumor antigens, MIλ ≠Ls are specifically suited for adoptive celluΩ€↓lar immunotherapy and are able to direc♦<σtly eradicate or facilitate eradication of ¶&each patient’s unique₽♠₹ cancer. WindMIL is currently sβ✔tudying MILs in multiσ↕£ple myeloma, non-small cell lung ♠₽cancer and squamous cell carcino≤π♠"ma of the head and neck, and plans to∑σ♥ expand into other solid tumors.“W≈indMIL is looking fo±₩₩φrward to working with™♥ the University of Californiφεa, Irvine on this exciting project and↓φΩ is optimistic that MILs may offer the po≥πtential to help patients with thesλ✔✔★e hard-to-treat diseases,” sa♦•€id Monil Shah, PharmD, MBA, Chief Devel<δ≥opment Officer at WindMIL.information↔₩σ source:pharma focus AsiaThe origiδδ♠nal link:https://www.pharmafo ∞cusasia.com/news/windmil-therapeut♣≤ics-and-university-of-california-irvin• σ∏e-announce-collaboration-to-c≈®ollect-bone-marrow-from-pa★$tients-with-gliomas2019 Asia-p§♥σacific pharma IP Lea™☆der Summit: http://en.zenseegroup.com/pδε↑>/510934/will be held in&n' bsp;Beijing on November 14-15, ±∑and will attract more than ✔ ↑500 industry experts from domestic and for₽€♠ eign pharmaceutical companies, biotechnolo•™gy companies, governments, associaσ ∏tions, law firms, intellectual property agen≤£÷☆ts and other companies to attend.Official regis↔₹↑tration and consultation∑β channels:Contact：AnnPhone: 021-65ε≈650305Email：Marketing@zen∏₽φ±seegroup.comhttp://en.zensee®♠γ¥group.com/p/510934/ -
1016
CRISPR Therapeutics and KSQ Therapeutics Aσ≈λnnounce License Agreement to Advance Compγ♠$anies’ Respective Cellδ×↓ Therapy Programs in Oncology
CRISPR Therapeutics and KSQ Therapeutics Ann'↕ounce License Agreement to ↕♠•Advance Companies’ Res≤☆>σpective Cell Therapy Progσ$rams in OncologyWEDNESDAY, OCTOBER 16, ♦ε£2019CRISPR Therapeutics, a biopharmace≠≥£↑utical company focused₽≥≠ on creating transformative gene-based medicin≈♦es for serious diseases,→↓& and KSQ Therapeutics, a biotechnology com✘≠✘₩pany using CRISPR technology to enable the comp♦↕any’s powerful drug discovery engine to achiβ"₽eve higher probabilities of success in drug deve∏≥lopment, today announced a license agreement wher ≤eby CRISPR Therapeutics will gain a'€ccess to KSQ intellectual pro©₹™perty (IP) for editing certain>∏>÷ novel gene targets in its ∞allogeneic oncology cell therapy programs☆¶®©, and KSQ will gain a♥'↔✔ccess to CRISPR Therapeutics’ IP fo₹¶r editing novel gene targets identifi←πed by KSQ as part of its current ±±£and future eTILTM (enginee¥®®red tumor infiltrating lymph←♠λλocyte) cell programs. The financ♥ ial terms of the agreement a™×re not being disclosed.“We are thrδ illed to gain access to CRISPR Therapeutics’ f☆∑γφoundational IP estate th≈λrough this agreement,” said David Meeker, M.D.,αΩΩλ Chief Executive Officer at KSQ Therapeutics.←≈ “Our eTILTM programs involve editing×¥£≥ gene targets in human TILs that were discovere§♥★d at KSQ by applying our proprietary CRISPRomi§ cs® approach to immune cells iΩ©n multiple in vivo models. This agreeme☆¥'nt clears an important path for us ↕≈to be able to bring these programs thγ rough development and commercializatio±∏n, leveraging CRISPR Thera☆αpeutics’ proprietary edi✘<©ting technology.”The gene targets wi↑±←thin the scope of the license ag✔'σreement were identifiedφ♣ using KSQ’s proprietary C↑₹RISPRomics® drug discovery engine, which ₹≥allows genome-scale, iε"↑¶n vivo validated, unbiased drug discovery. These₩×> specific targets were uncovered "↑in screens to identifyδ ₹∞ genetic edits that could enh$£ance the functionality and ≤≈§•quality of adoptive cell therapies in oncology<≥σ↔.“KSQ has built an industry-leading ¥☆α±platform to screen for novel gene targe₩♠ts using its technology, ∑₹♣and has identified a group of targets that coul♥εd help unlock the full potential o↕₩÷f adoptive cell therapy in oncol¶βogy,” said Samarth Kulkarni, Ph.D., Chief Executiπ₩×ve Officer at CRISPR Therapeutics. “As a result o×φ✘↓f this license agreeme≥♥♠nt, CRISPR Therapeutics will have the oppo♣αrtunity to bring thes¥ ✔₩e novel targets into our leading allogeneic CAφ¶₹R-T development platf♣↓γ¶orm to further strengthen our future programs in>∞§✘ this important therapeutic area.”informatioα©☆n source:pharma focus AsiaTh≤" <e original link:https:https://www.pharmafocusasi× ∏∑a.com/news/crispr-therapeutics-and-ksq-therapeuti&β<cs-announce-license-agreement✔ λ-to-advance-companies-respective-cell-therap☆¶y-programs-in-oncology2019 Asia-pacific pharma ≥Ω¶$IP Leader Summit: http://en.zenseegroup.com/p/51★↓0934/ will be held in&nbs↓&★p;Beijing on November 14-15, and₽>← will attract more than ∞€500 industry experts from domest" §αic and foreign pharmaceutical companies, bioΩ>technology companies, governments, association€₽>s, law firms, intellectual property agents and'♠ other companies to atten¥♥♣d.Official registration and consultation chaπ✘∞nnels:Contact：AnnPhone: 021-65650305Email：♦≥δ∑Marketing@zenseegroup.comhttp://en.zenseegroupε♣≤∏.com/p/510934/ -
1015
Shionogi enters into a new lic♠¶&ense agreement and research collaboration'→ for the treatment of my₩©$cobacterial diseases with H₩$siri Therapeutics, Inc.
Shionogi enters into a neπ↔↕§w license agreement a™₽nd research collaboration for the tre₹♠← atment of mycobacterial diseases wi✔φβth Hsiri Therapeutics, Inc.MONDAY, OCT₹&•OBER 14, 2019Shionogi & Co., Ltd. today ÷β≤announced that it has ent↔Ω±ered into a new license agreement with Hsiri≠✔ Therapeutics, Inc. (Head Office: Media♣ ∞✘, PA, USA; President↔™ and CEO: William Claypool, M.D.; hereaft≤≠∑er "Hsiri") regarding a collaborativ±↔≈e research and development prΩ₽★ogram to discover and develop ad⩶ditional novel therapeutics for¶& non-tuberculous mycobact↕•σ®erial (NTM) diseases and ★¥&¶tuberculosis (TB). This new collaboratio®$n will include technology that complements Shi←♥≥onogi's earlier collabora≥¶≤tion arrangement with Hsiri.≈γThe new technology to be licensed≤ from Hsiri has a novel mechanism of £←∞€action, will be complementary to Shiono≤₽δgi's current research with Hsiri, and is a←εnticipated to be more effective than current ther ÷&apies for mycobacterial✘↔ infections. Shionogi's strength in s→₩←≥mall molecule drug discovery and development in β≥the antibacterial area will suppoλ"↓rt development of Hsiri's innovative therapeut£™∞ics in this collaborative progra↕m. Under the terms of thisσ&> agreement, Shionogi will have ex÷☆♣±clusive worldwide rig★✔hts to develop, manufacture, and commercial↓"$ize the compounds generated from the colla∏≥boration. Hsiri will receive an upfroγ&¥nt license fee, potential d ¥•evelopment milestones, and royalty payments b♣®±'ased on sales from Shionogi.It is reportedΩ© that the number of patien₽÷δts suffering from NTM diseases has been incre→♣≈asing, especially in developed coun÷×tries, in recent years. There is a medical neα™↕≈ed to develop novel anti-NT&>§φM drugs because of the long durat♦∞ion of treatment and insufficient treatm≠$δent outcome of curreδ←nt therapeutics. TB is one of th∏₩↔€e three major infectious diseases i↓∑¥n the world, and new •∏♥§cases of TB are estimated to be®☆₹ 10.4 million/year. Multidr₩σ•ug-resistant TB (MDR-TB) and extensively dαφrug-resistant TB (XDR-TB) have be≤≥↓come a major public health cβ↑¥oncern, and novel drugs for MDR-TB and XDR-T↑≈γB are anticipated.Shionog€←→✔i's research and development targets in>β♠♦fectious disease as one of its priority areasε€, and Shionogi have positioned "protecting peopl★®₽★e from the threat of Ω"infectious diseases" as one of its social∑∑← mission targets. Through this cooperation, Shion©♦φσogi strives constantly∑ to bring forth innovative drugs for the treaσβtment of infectious diseases,∞✔< to protect the health of patients we serve.iβ₩$nformation source:pharma focus AsiaThe oδ∞riginal link:https:https®÷:https://www.pharmafocu©ε¶☆sasia.com/news/shionogi-enters-int≤€π∑o-a-new-license-agreement-and-research-c←∞ollaboration-for-the-treatment-of-myc∏∞obacterial-diseases-with-hsiri-therapeuti≈εαcs-inc2019 Asia-pacific pharma IP Leader Summit: ¥↔₽™http://en.zenseegroup.com/p/510934/ wαε αill be held in Beijing&nbs≥♦₩₩p; on November 14-15, and w←→₩ ill attract more than 500 industry experts from ∏∞domestic and foreign pharmaceutical compan↔←♦ies, biotechnology companies, gov↔≤Ω☆ernments, associations, law firms, intel★≤φ¥lectual property agents and other companies to↑&β attend.Official registration and consultation<©₹± channels:Contact：AnnPho₩≥ &ne: 021-65650305Email：Marke←βting@zenseegroup.comhttp://en.zenseegroup.com/pΩ≠/510934/ -
1014
Advaxis and UCLA Enter Collaboration for Gliobl©∑Ω'astoma Immunotherapy Discov≥>•λery Research
Advaxis and UCLA Enter Collaboration for Gliobla∞ £stoma Immunotherapy Disc§↑✘overy ResearchFRIDAY, OCTOBγ•φ←ER 11, 2019Advaxis, Inc.β₽, a clinical-stage biotechnology company focused ₩on the discovery, development and commerciali→™zation of immunotherapy products, tod♥©ay announced a research collaboration agreement∑≠→™ with the University of Californδπσia Los Angeles (UCLA) to conduct preclinical★₽ studies evaluating the Companπ÷₹y’s Lm technology in mouse tumor models o♣ ₹"f glioblastoma multiforme (GBM). Spe∑♥☆cifically, the collaboratφ₽ion with Dr. Vaithi Aru®$≠mugaswami’s group at UCLA’s←÷>• Department of Molecular and Medical Phar •↑macology will investigate anti-tumor immunity a★←nd anti-tumor responses gen"✔erated by Lm vaccines that express $✔diverse glioblastoma neoantigens.“We ar≈¶e excited that Dr. Arumuga↕§✘÷swami and his colleaλ€✘gues at UCLA will investigate the potential €βδ≥of our Lm technology platform in GB≤↓✘M, one of the deadliest canc×♣ers,” said Andres Gutβπ↔ierrez, Executive Vice President and Chief Med∞&ical Officer of Advaxis. “Contra≠>βry to other tumor types, GBM has not seen much×★ success in targeting byφΩ immunotherapeutic agents due to a lo™✔w tumor mutation burden, high tumor het≈€∑↑erogeneity and presence of the blood brai₽≈↑♥n barrier, among other factors. Hence, →™$Dr. Arumugaswami’s character÷☆ization of the neoantigen landscape an±₹✘d immune responses to Lm- constr ☆ucts may lead to the development of nλ "ovel therapies with clinical activity inΩε™$ this elusive cancer.”informati≠ •on source:pharma focus Asia≥Ω"The original link:https:https:ht¥©★•tps://www.pharmafocusasia.com/news/advaxisλ -and-ucla-enter-collaboration-for-gli✔oblastoma-immunotherapy-discovery-research'↑×2019 Asia-pacific pharma IP Lead€←er Summit: http://en.zensee♠™β♦group.com/p/510934/will be held ↑γ→in Beijing on&n✘♥εbsp;November 14-15, and will attract mo≠¥re than 500 industry e∞ ₹±xperts from domestic★φ× and foreign pharmaceutical companies, biot®©echnology companies, governm"&£ents, associations, law firms, intel$↔≈ lectual property agents and other cΩλompanies to attend.Official ♦≤×registration and consultation channels:Con♥πδtact：AnnPhone: 021-65650305Email：Marketing@φzenseegroup.comhttp://en.zenseeg↕σ←®roup.com/p/510934/ -
1011
Viela Bio Enters Strategic Collaboration with≥✔ Mitsubishi Tanabe Pharma t≥>>o Develop and Commercial©←↓<ize Inebilizumab for Autoiβ$mmune Diseases in Japan and Other As§<φ ia Regions
THURSDAY, OCTOBER 10, 2019Viela Bio, Inc.> • and Mitsubishi Tanabe Pharma Corporat♣∏ion (“MTPC”) today a✔>nnounced a collaboration focused oαδn the development and co•φ§↔mmercialization of inebilizumab – Viel₹Ωa’s humanized anti-CD19 monoclonβ α↓al antibody – in nine Asia regions®&Ω♥ for neuromyelitis optica spect↑'rum disorder (NMOSD)±↕Ω, as well as other pot✘♦<ential future indications.“This partnership addγ₽★s to our ability to commercialize inebilizu← Ωσmab globally, subject to regulatory∞↔ approval,” commented Bi★¶×©ng Yao, Ph.D., Viela’s Ex↔↑ecutive Chairman and Chief Executive Officer.&™↔€ “As a well-established pharm↑∑ ₹aceutical company in Japan, Mitsubish•↑≠×i Tanabe has strong produc× t development and comme™₹rcialization capabilities in Asia,∞♠γ≈ and we believe, is an"©γ≠ ideal partner for expanding inebil≤σ∏izumab’s potential reach to thousands of additionλ®♠al patients in need of viable treatments, with NM→δΩ≠OSD as an initial indicat∑φ♦ion.”Under terms of the coll∏¶ασaboration, Viela will receive an up-frontπ★ licensing fee of $30 &☆↔↓million as well as additional payments §β¥contingent on certain develoγγ$pment and commercial milestones, plus payments ba∏→±sed, in part, on sales revenue. MTPC≈ α♠ will be responsible for leading develop¶γ≠$ment and commercializ★←σ•ation of inebilizumab in Japan, Thailand, So♥±™uth Korea, Indonesia, Vietnam, Malaysiaφ, Philippines, Singapore, and Taφ"αiwan.“Our organization is∞<≤ delighted to partner with Viela to deveβ♥δ♥lop and commercialize their promising product can♣≈σφdidate inebilizumab for autoimmune and in÷δflammatory diseases,” ®δΩsaid Masayuki Mitsuka, MTP® ≤C President & Representatλ™∏£ive Director. “Inebilizumab is an exciting pro™ duct candidate that, ba ׶sed on the results from the N-MOmentum pivoε&tal study, is well-positioned to prov↕∏♠ide meaningful benefit ±for patients with NMOSD, and potentiall≥→βy additional diseases, subj'φect to regulatory approval. We are excited to w♣→<ork with Viela to advance i≈ ↓nebilizumab in Japan and other Asia r¶↓egions, and look forwaΩ↑©rd to a productive partnership between our co∑♠mpanies.”The U.S. Food and Drug Admin↓↔≠istration (FDA) recently accepted for review π✔↕ Viela’s Biologics License Application (BLA) f→<↔or inebilizumab for the treat→εment of NMOSD. information source∑$✔≤:pharma focus AsiaThe< original link:https:https://www.pharmafocus≤£ asia.com/news/viela-bio-enters-¶↑strategic-collaboration-with-mitsubishi-tanab₩♠π≥e-pharma-to-develop-a♣ε∞₩nd-commercialize-inebilizumab-for-autoimmune★Ω-diseases-in-japan-and-other-♥π∑εasia-regions2019 Asia-pacific pharma IP ₩≈<Leader Summit: http://en.zeβ™♥nseegroup.com/p/510934/will be hel♥•₹'d in Beijing on November 14-∑"15, and will attract more than 50₽∞£×0 industry experts from domesπ tic and foreign pharmaceutical companies, bio'>♠≥technology companies, governmλ♦↔ents, associations, l₽€ aw firms, intellectual property agents and other♣β♦λ companies to attend ε♦♠.Official registration and consultation≤ ☆☆ channels:Contact：AnnPhoΩ☆ φne: 021-65650305Email：Marketing@zenseegrou ∏₹p.comhttp://en.zenseegroup.com/♦ p/510934/
Contact Us
Zensee_Daystar onlin®♣≤e
© 2011-2016